Skip to content

Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

Magnesium Sulfate Versus Placebo for Tocolysis in Preterm Premature Rupture of Membranes

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00463736
Enrollment
4
Registered
2007-04-20
Start date
2007-04-30
Completion date
2010-03-31
Last updated
2016-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm Premature Rupture of Membranes

Keywords

short term tocolysis, preterm premature rupture of membranes

Brief summary

Study compares the outcomes of women between 26 and 32 wks gestation with rupture of membranes. Women randomized to receive tocolysis with magnesium sulfate x 48 hrs or placebo of saline IV x 48 hrs. Antibiotics and antenatal steroids given to both groups.

Detailed description

The majority of studies of the effectiveness of tocolysis with PPROM were in the 1980s prior to the commmon usage of antenatal steroids and prophylactic maternal antibiotics. In most studies, tocolysis was not attempted prior to the onset of labor in this group of women. The ACOG Practice Bulletin of June 1998 concedes that the recommendation of tocolysis to permit administration of steroids and maternal antibiotics is based primarily upon consensus, not consistent scientific evidence. The purpose of this study, which will randomize 128 subjects to tocolysis or no tocolysis, is to prospectively assess whether short term (48 hr) tocolysis affords benefit to women and babies between 26 and 32 weeks gestation with PPROM. Subjects will be enrolled at 1-2 high risk hospitals in Chattanooga and Knoxville. All English and Spanish speaking women 18-45 years with PPROM and cervical dilation \<4 will be eligible. Women with suspected intrauterine infection, positive fetal lung maturity, or \> 6 hours tocolysis at time of admission will be excluded. Both groups of women will receive continuous fetal monitoring, antibiotics, and antenatal steroids (if not previously administered). Both groups will be evaluated every 2-4 hours for fetal and maternal well being. Both groups will receive IVF at 125cc/hr, and the treatment group will be loaded with 4 grams of magnesium sulfate and receive maintainence dose of 2 grams/hr x 48 hrs.

Interventions

DRUGMagnesium sulfate

Sponsors

Regional Obstetrical Consultants
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* English or Spanish speaking * preterm premature rupture of membranes * 26 - 32.6 weeks gestation * cervical dilation \</= 4 cm

Exclusion criteria

* suspected intrauterine or intraamniotic infection * \> 6 hours of tocolysis prior to admission * positive fetal lung maturity

Design outcomes

Primary

MeasureTime frameDescription
hours of latency to delivery0 hours to > 168 hoursfrom start of study drug to delivery

Secondary

MeasureTime frameDescription
maternal postpartum length of stay0 hours to > 168 hoursfrom start of study drug to delivery
maternal infection rates0 hours to > 168 hoursfrom start of study drug to maternal discharge from hospital
neonatal ventilator days0 to 28 daysfrom delivery to 28 days of life
neonatal early onset infection0 to 28 daysfrom delivery to 28 days of life
neonatal length of stay0 to 28 daysfrom delivery to 28 days of life

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026